Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Youn H. Kim et al.|The Lancet|2017Cited by 580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionMartina Sanlorenzo, Susana Ortiz‐Urda, Igor Vujic et al.|JAMA Dermatology|2015Cited by 452
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017Franz Trautinger, Robert Knobler, Johanna Eder et al.|European Journal of Cancer|2017Cited by 449
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic ModelJulia Scarisbrick, Henry K. Wong, Pierluigi Porcu et al.|Journal of Clinical Oncology|2015Cited by 419
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Christian U. Blank et al.|The Lancet Oncology|2021Cited by 389